Prudential Financial
TSHA icon

Prudential Financial’s Taysha Gene Therapies TSHA Stock Holding History

Prudential Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
39,040
+5,220
+15% +$30.9K ﹤0.01% 2142
2026
Q1 		$151K Sell
33,820
-52,910
-61% -$246K ﹤0.01% 2184
2025
Q4 		$477K Buy
86,730
+58,385
+206% +$284K ﹤0.01% 1846
2025
Q3 		$92.7K Buy
28,345
+5,555
+24% +$15.7K ﹤0.01% 2286
2025
Q2 		$52.6K Buy
22,790
+7,650
+51% +$16.6K ﹤0.01% 2342
2025
Q1 		$21K Buy
15,140
+2,150
+17% +$3.6K ﹤0.01% 2253
2024
Q4 		$22.5K Buy
12,990
+1,800
+16% +$3.73K ﹤0.01% 2270
2024
Q3 		$22.5K Hold
11,190
– – ﹤0.01% 2690
2024
Q2 		$25.1K Sell
11,190
-7,860
-41% -$22.9K ﹤0.01% 2663
2024
Q1 		$54.7K Hold
19,050
– – ﹤0.01% 2582
2023
Q4 		$33.7K Buy
19,050
+1,800
+10% +$3.59K ﹤0.01% 2585
2023
Q3 		$54.5K Buy
+17,250
New +$32.2K ﹤0.01% 2492

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prudential Financial's TSHA Position: Q2 2026 in Review

Prudential Financial increased its Taysha Gene Therapies (TSHA) stake by 15% in Q2 2026, buying an estimated $30.9K and bringing the position to 39,040 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Prudential Financial first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. The position peaked at $477K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Prudential Financial held 39,040 shares of Taysha Gene Therapies worth $266K as of Q2 2026.
  • Prudential Financial bought 5,220 Taysha Gene Therapies shares in Q2 2026, an estimated $30.9K.
  • Taysha Gene Therapies made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2142 holding.
  • Prudential Financial first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
  • Prudential Financial's Taysha Gene Therapies position peaked at $477K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.